Are you Dr. Mielcarek?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 20 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
Ambulatory Clinic
825 Eastlake Avenue East
Seattle, WA 98109Phone+1 206-288-1000
Summary
- Dr. Marco Mielcarek, MD is an oncologist in Seattle, Washington. He is currently licensed to practice medicine in Washington, Montana, and Hawaii. He is affiliated with Fred Hutch Cancer Center and UW Medicine/University of Washington Medical Center.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2000 - 2003- University of WashingtonResidency, Internal Medicine, 1998 - 2001
Freie University Berlin Faculty of MedicineClass of 1986
Certifications & Licensure
MT State Medical License 2022 - 2026
WA State Medical License 2000 - 2025
HI State Medical License 2018 - 2024- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma Start of enrollment: 2002 Oct 01
- Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant Start of enrollment: 2006 May 01
- Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma Start of enrollment: 2008 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsLate Effects of Severe Acute Graft-versus-Host Disease on Quality of Life, Medical Comorbidities, and Survival.Nahid Rashid, Elizabeth F Krakow, Albert C Yeh, Masumi Ueda Oshima, Lynn Onstad
Transplantation and Cellular Therapy. 2022-12-01 - 69 citationsEffectiveness and safety of lower dose prednisone for initial treatment of acute graft- versus -host disease: a randomized controlled trialMarco Mielcarek, Terrence Furlong, Barry E. Storer, Margaret L. Green, George B. McDonald
Haematologica. 2015-06-01 - 22 citationsAllogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects.Rainer Storb, Boglarka Gyurkocza, Barry E. Storer, David G. Maloney, Mohamed L. Sorror
Biology of Blood and Marrow Transplantation. 2013-05-01
Press Mentions
- Patients Navigate Cancer During COVID-19 PandemicOctober 13th, 2020
How to Exceed 5-Year Post-Transplant Survival in the U.S.May 5th, 2018
Fred Hutch Doctor Takes on Life-Threatening Stem Cell Transplant ComplicationFebruary 13th, 2017- Join now to see all
Other Languages
- German
